Oltipraz chemoprevention trial in Qidong, People's Republic of China: Modulation of serum aflatoxin albumin adduct biomarkers

Cancer Epidemiology Biomarkers and Prevention

Volumn 7, Issue 2, 1998, Pages 127-134

  Kensler, Thomas W ^d,e   He, Xia ^d   Otieno, Monicah ^d   Egner, Patricia A ^d   Jacobson, Lisa P ^d   Chen, Baibai ^d   Wang, Jia Sheng ^d   Zhu, Yuan Rong ^a   Zhang, Bao Chu ^a   Wang, Jin Bing ^a   Wu, Yan ^a   Zhang, Qi Nan ^a   Qian, Geng Sun ^b   Kuang, Shuang Yuan ^b   Fang, Xi ^b   Li, Yan Feng ^b   Yu, Lu Yi ^c   Prochaska, Hans J ^f   Davidson, Nancy E ^e   Gordon, Gary B ^e   Gorman, Mary B ^d   Zarba, Audrey ^d   Enger, Cheryl ^e   Muñoz, Alvaro ^d   Helzlsouer, Kathy J ^d,e   Groopman, John D ^d,e   more..

^a QIDONG LIVER CANCER INSTITUTE   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

^c FUDAN UNIVERSITY   (China)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ALBUMIN; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE; OLTIPRAZ; PLACEBO;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CHINA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DNA ADDUCT; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; FOOD CONTAMINATION; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AFLATOXINS; AGED; ALBUMINS; ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PYRAZINES; RADIOIMMUNOASSAY; RISK ASSESSMENT;

EID: 0343545529     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kensler, T. W. Chemoprevention by inducers of carcinogen detoxification enzymes. Environ Health Perspect., 104(Suppl 4): 965-970, 1997.
2. Wattenberg, L. W. Chemoprevention of cancer. Cancer Res , 45. 1-8, 1985.
3. Zhu, Y-R , Chen, J-G., and Huang. X Y. Hepatocellular carcinoma in Qidong County. In: Tang, Z Y. (ed) Primary Liver Cancer, pp. 204-222. Beijing: China Academic Publisher, Springer-Verlag, 1989.
4. Yu, S-Z Primary prevention of hepatocellular carcinoma. J Gastroenterol. Hepatol., 10: 674-682, 1995
5. Ross, R K , Yuan, J-M., Yu, M. C , Wogan, G. N., Qian, G-S , Tu, J-T., Groopman, J. D., Gao Y-T., and Henderson, B E Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339: 943-946, 1992
6. Qian, G-S., Ross, R. K., Yu, M. C. Yuan, J-M., Gao, Y-T , Henderson, B. E., Wogan, G. N , and Groopman, J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomark. Prev , 3: 3-10, 1994
7. Wang, J-S., Qian, G-S , Zarba, A., He, X., Zhu, Y-R., Zhang, B-C., Jacobson, L., Gange, S J., Muñoz, A , Kensler, T. W., and Groopman, J. D Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin. Qidong County. People's Republic of China. Cancer Epidemiol. Biomark. Prev., 5: 253-261, 1996.
8. Kuang, S-Y , Fang, X , Lu, P-X , Zhang, Q-N , Wu, Y , Wang, J-B , Zhu, Y-R., Groopman, J. D , Kensler, T. W , and Qian, G-S. Aflatoxm-albumin adducts and risk for hepatocellular carcinoma in residents of Qidong, People's Republic of China. Proc. Am Assoc. Cancer Res, 37 252, 1996
9. Wang, L-Y., Hatch, M , Chen, C-J , Levin, B., You, S-L , Lu, S-N , Wu, M-H , Wu, W-P., Wang, L-W , Wang, Q., Huang, G-T Yang, P-M., Lee, H-S., and Santella, R. M. Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer, 67: 620-625, 1996.
10. Kensler, T W., Davis, E. F., and Bolton, M. G. Strategies for chemoprotection against aflatoxin-induced liver cancer. In. D. L. Eaton and J. D. Groopman (eds.) The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance, pp. 281-306 San Diego: Academic Press, Inc , 1994.
11. 1. In: B W Stewart, D. McGregor, and P Kleihues (eds.). Principles of Chemoprevention, pp 175-187. Lyon, France. IARC, 1996
12. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51: 5501-5506, 1991.
13. Bolton, M. G., Muñoz, A., Jacobson, L. P., Groopman, J. D., Maxuitenko, Y. Y , Roebuck, B. D., and Kensler, T. W. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res., 53 3499-3504, 1993
14. Egner, P. A., Gange, S. J., Dolan, P. M , Groopman, J. D., Muñoz, A., and Kensler, T. W. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis (Lond.) 16: 1769-1773, 1995.
15. Kensler, T. W., Egner, P. A., Dolan, P. M., Groopman, J. D., and Roebuck, B D. Mechanism of protection against aflatoxin tumongenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 47: 4271-4277, 1987.
16. Davidson, N E., Egner, P A., and Kensler, T. W. Transcriptional control of glutathione S-transferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz) in rat liver. Cancer Res , 50: 2251-2255, 1990.
17. Morel, F , Fardel, O., Meyer, D. J., Langouët, S., Gilmore, K. S., Meunier, B., Tu, C-P D., Kensler, T. W., Ketterer, B., and Guillouzo, A. Preferential increase of glutathione S-transferase class a transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolethiones. Cancer Res., 53: 231-234, 1993
18. 1 metabolism. FASEB J., 5: A1517, 1991.
19. 1 metabolism in human hepatocytes in primary culture Cancer Res., 55: 5574-5579, 1995.
20. 1 excretion in rat urine during dietary intervention with oltipraz. Carcinogenesis (Lond), 17: 1385-1388, 1996.
21. Benson, A. B , III. Oltipraz: a laboratory and clinical review J. Cell. Biochem, 17F: 278-291, 1993.
22. Gupta, E., Olopade, O. I., Ratain, M J., Mick, R., Baker, T. M., Berezin, F. K , Benson, A. B., III, and Dolan, M. E. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent Clin. Cancer Res., 1 1133-1138, 1995.
23. O'Dwyer, P. J , Szarka, C. E , Yao, K-S., Halbherr, T. C., Pfeiffer, G. R., Green, F., Gallo, J M., Brennan, J., Frucht, H., Goosenberg, E. B , Hamilton, T. C., Litwin, S., Balshem, A M , Engstrom, P. F., and Clapper, M L. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J. Clin. Invest., 98: 1210-1217, 1996.
24. Jacobson, L. P., Zhang, B-C., Zhu, Y-R., Wang, J-B., Wu, Y., Zhang, Q-N , Yu, L-Y., Qian, G-S, Kuang, S-Y , Li, Y-F., Fang, X., Zarba, A., Chen, B , Enger, C., Davidson, N. E., Gorman, M B., Gordon, G. B , Prochaska, H J , Egner, P A , Groopman, J. D., Muñoz, A , Helzlsouer, K. J., and Kensler, T. W. Oltipraz Chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol. Biomark. Prev , 6: 257-265, 1997.
25. Egner, P A., Kensler, T. W., Prestera, T., Talalay, P., Libby, A. H., Joyner, H. H., and Curphey, T. J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones Carcinogenesis (Lond ), 15: 177-181, 1994
26. Groopman, J D , Donahue, P. R., Zhu, J., Chen, J-S , and Wogan, G. N Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl. Acad. Sci. USA, 82 6492-6496, 1985.
27. Wang, J-S., Strickland, P T., Abubaker, S , He, Z , and Groopman, J. D. Novel aflatoxin-lysine specific monoclonal antibodies for biomarker studies Fundam Appl. Toxicol., 30S (Suppl.). 221, 1996
28. Gange, S. J , Muñoz, A., Wang, J-S., and Groopman, J. D. Variability of molecular biomarker measurements from nonlinear calibration curves. Cancer Epidemiol Biomark. Prev , 5: 57-61, 1996
29. Chen, H., Sandler, D., Taylor, J. A., Shore, D. L., Liu, E , Bloomfield, C., and Bell, D. A Increased risk for myelodysplastic syndromes among those with glutathione S-transferase θ 1 (GSTT1) gene defect. Lancet, 347: 295-296, 1996.
30. Bell, D. A., Taylor, J A., Paulson, D , Robertson, D., Mohler, J , and Lucier, G. W. Genetic risk and carcinogen exposure a common inherited defect of the carcinogen metabolism gene glutathione transferase Mu (GSTM1) is associated with increased susceptibility to bladder cancer. J. Natl. Cancer Inst. (Bethesda), 85: 1159-1164, 1993.
31. Pemble, S., Schroeder, K. R., Spencer, S. R., Meyer, D. J., Hallier, E , Bolt, H. N , Ketterer, B , and Taylor, J B. Human glutathione S-transferase θ (GSTT1) cDNA cloning and the characterization of a genetic polymorphism. Biochem J , 300: 271-276, 1994.
32. Laird, N M., and Ware, J. H. Random-effects models for longitudinal data Biometrics, 38. 963-974, 1982.
33. Groopman, J D., Wogan, G. N., Roebuck, B D, and Kensler, T. W. Molecular biomarkers for aflatoxins and their application to human cancer prevention. Cancer Res., 54 (Suppl.): 1907s-1911s, 1994.
34. Rosenoer, V M. Clinical aspects of albumin metabolism. In: V M. Rosenoer, M. Oratz, and M. A. Rothschild (eds.). Albumin Structure, Function and Uses, pp. 345-367. Oxford, United Kingdom: Pergamon Press, 1977.
35. Kensler, T. W , Gange, S. J , Egner, P. A., Dolan, P. M., Muñoz, A., Groopman, J. D., Rogers, A E., and Roebuck, B. D. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer Cancer Epidemiol. Biomark. Prev., 6 603-610, 1997.
36. Groopman, J. D., and Kensler, T. W. Molecular biomarkers for human chemical carcinogen exposures. Chem. Res. Toxicol., 6: 764-770, 1993.
37. Perera, F. P., and Weinstein, I B. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J. Chronic Dis. 35: 581-600, 1982.
38. Kensler, T. W , Groopman, J D., and Wogan, G. N. Carcinogen-DNA and protein adduct biomarkers for cohort selection and as modifiable endpoints in chemoprevention trials In: B W. Stewart, D. McGregor, and P. Kleihues (eds) Principles of Chemoprevention, IARC Scientific Publ. No. 139, pp. 237-248, Lyon, France: IARC, 1996.
39. 1. Carcinogenesis (Lond), 9: 1323-1325, 1988
40. Wild, C. P., Hudson, G. J , Sabbioni, G., Chapot, B., Hall, A J , Wogan, G. N., Whittle, H , Montesano, R , and Groopman, J D. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomark. Prev., 1: 229-234, 1992
41. 14C-oltipraz in animals. Arzneim. Forsch., 35. 1431-1436, 1985
42. Primiano, T., Egner, P. A., Sutter, T. R., Kelloff, G. J., Roebuck, B. D , and Kensler, T W. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res., 55: 4319-4324, 1995.
43. 1 exo- and endo-epoxides by rat and human glutathione S-transferases. Chem Res. Toxicol , 5: 470-478, 1992